affinity biologicals/Apolipoprotein-H Paired Antibody Set/APOH-EIA

Description

Apolipoprotein-H Paired Antibody Set

Affinity’s Apolipoprotein-H Paired Antibody Set consists of matched capture and detecting antibodies that have been titrated and optimized for use in sandwich style ELISA assays. The product as provided contains sufficient capture and detecting antibodies for five full 96-well microplates and contains a detailed protocol sheet containing directions for use, recipes for solutions and sources for additional materials required. This Apolipoprotein-H Paired Antibody Set is intended to facilitate the end user in establishing an “in-house” immunoassay for research purposes only and must not be used for diagnostic applications.  Assay validation is the responsibility of the end user.

Product Code: APOH-EIA

Supplied Materials:

1. Capture Antibody (APOH-EIA-C): One yellow-capped vial containing 0.4 ml of polyclonal affinity purified anti-B2GP1 antibody for coating plates.
2. Detecting Antibody (APOH-EIA-D):  One red-capped tube containing 0.4 ml of peroxidase conjugated affinity-purified polyclonal anti-B2GP1 antibody for detection of captured B2GP1.

Related Products:  VisuLize Buffer Pak APOH Deficient Plasma

Species Cross Reactivity: View Chart

Product Datasheet: APOH Apolipoprotein-H Beta-2-Glycoprotein-2 Antigen Matched Pair Antibody Set for ELISA - APOH-EIA

Description of Beta-2-Glycoprotein-1 (Apolipoprotein-H, APOH)

Beta-2-Glycoprotein 1 (B2GP1), also known as Apolipoprotein-H (APOH), is a plasma glycoprotein that circulates at a concentration of 200 ug/ml (4 μM). Synthesized in the liver, β2GP1 is a single chain molecule of 48 kDa, consisting of five repeating internally disulphide-bonded structures referred to as sushi domains. Relative to other glycoproteins, β2GP1 has an unusually high content of cysteine (6.2%), proline (8.3%) and carbohydrate (19%). Almost half the circulating β2GP1 in plasma is associated with lipoproteins of all major fractions. β2GP1 has been demonstrated to bind negatively charged phospholipids, heparin and platelets. Although the precise function(s) are as yet unknown, β2GP1 has been demonstrated to interfere with blood coagulation by competitively binding to negatively charged phospholipid surfaces exposed during cell activation or damage. Recent evidence also implicates β2GP1 as a cofactor recognized by anti-phospholipid antibodies present in some autoimmune disorders such as systemic lupus erythematosus (SLE)^1-3.

References and Review

1. Lee, NS, Brewer HB Jr., Osborne JC Jr.; β2Glycoprotein I: Molecular Properties of an Unusual Apolipoprotein, Apolipoprotein H; JBC 258, pp 4765-4770, 1983.
2. Schousboe I; β2Glycoprotein I: A Plasma Inhibitor of the Contact Activation of the Intrinsic Blood Coagulation Pathway. Blood 66, pp 1086-1091, 1985.
3. Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaal RFA; Prothrombinase activity of human platelets is inhibited by β2Glycoprotein I; Biochimica et Biophysica Acta 884, pp 142-149, 1986.